Digital repository of Slovenian research organisations

Search the repository
A+ | A- | Help | SLO | ENG

Query: search in
search in
search in
search in

Options:
  Reset


Query: "author" (Tanja Južnič Šetina) .

1 - 10 / 29
First pagePrevious page123Next pageLast page
1.
Mosunetuzumab v monoterapiji pri refraktarnem folikularnem limfomu : klinični primer
Kristina Levpušček, Tanja Južnič Šetina, Milica Miljković, 2024, published professional conference contribution

Keywords: internistična onkologija, limfom, kemoterapija
Published in DiRROS: 22.04.2024; Views: 157; Downloads: 44
.pdf Full text (771,29 KB)

2.
Testing of mechanisms of action of rituximab and clinical results in high-risk patients with aggressive CD20+ lymphoma
Barbara Jezeršek Novaković, Vladimir Kotnik, Tanja Južnič Šetina, Marjeta Vovk, Srdjan Novaković, 2007, original scientific article

Abstract: Background. Rituximab has been applied successfully in the treatment of indolent and aggressive CD20 positive B cell lymphomas, yet the exact in vivo mechanisms of its action have not been unambiguously explained. This study wastherefore aimed to confirm the presumed major mechanisms of action of rituximab and concomitantly to assess the effectiveness of first-line chemoimmunotherapy in high-risk patients with aggressive CD20 lymphomas. Patients, materials and methods. The activity of rituximab was tested in vitroon Raji and SU-DHL-4 cells using the cell proliferation assay and flow cytometry. In the clinical part of the study, 20 high-risk patients with aggressive CD 20 lymphomas were treated with R-CHOP. Results. Only complement-mediated cytotoxicity was observed under the in vitro applied experimental conditions. Neither the direct apoptotic effect nor the antibody-dependent cell-mediated cytotoxicity was detected probably due to a too low concentration of rituximab and a too low ratio of cytotoxic lymphocytes to tumor cells. The treatment outcome in patients was excellent since complete remissions were achieved in 90% of poor-risk patients at the end of primary treatment and 80% of patients were disease free at 18.5 months median observation period. Conclusions. According to our results, the complement-dependent cytotoxicity is an important mechanism of rituximab action in vitro. To achieve direct apoptosis, higher concentrations than 20 micro g/ml of rituximab should be used, while for an effective antibody-dependent cell-mediated cytotoxicity, the ratio of cytotoxic lymphocytes to tumor cells should be higher than 1:1. In the high- risk patients with aggressive CD20 lymphomas, the addition of rituximab to CHOP substantially improves the therapeutic results.
Published in DiRROS: 22.02.2024; Views: 221; Downloads: 61
.pdf Full text (232,23 KB)

3.
Folikularni limfom : vodnik za bolnike
Tanja Južnič Šetina, 2022, not set

Keywords: etiologija, komplikacije, recidiv, bolniki, psihološka pomoč
Published in DiRROS: 24.07.2023; Views: 459; Downloads: 94
.pdf Full text (691,04 KB)

4.
5.
Hiperkalcemija
Tina Zupančič, Tanja Južnič Šetina, 2022, published scientific conference contribution

Abstract: Hiperkalcemija je relativno pogosta elektrolitna motnja pri bolnikih z maligno boleznijo, običajno je prisotna pri napredovalem stadiju in nosi slabšo prognozo. Hiperkalcemija je lahko blaga, srednja ali huda, bolniki so ob tem lahko povsem asimptomatski ali pa imajo močno izražene simptome (bolečine v trebuhu – renalna/biliarna kolika, pankreatitis, bruhanje, zaprtje, bolečine v kosteh, motnje osebnosti in zavesti) ter so tudi ogroženi za nenadni srčni zastoj. Hiperkalcemija pri maligni bolezni nastane zaradi t.i. humoralnega mehanizma, ki katerem maligne celice izločajo parathormonu podoben protein, kostnih zasevkov, pospešenega nastajanja aktivne oblike vitamina D (kalcitriol) ali ektopičnega nastajanja parathormona. Pri zdravljenju hudo simptomatske hiperkalcemije lahko uporabimo kalcitonin, ključni pa so obilna parenteralna hidracija, forsirana diureza s furosemidom, antiresorptivna zdravila (v urgentnih situacijah zolendronska kislina, glede na vzrok kasneje lahko denosumab) ter seveda specifično onkološko zdravljenje.
Keywords: neželeni učinki, bolniki, sistemsko zdravljenje
Published in DiRROS: 17.01.2023; Views: 580; Downloads: 120
.pdf Full text (99,87 KB)

6.
7.
8.
Folikularni limfom : vodnik za bolnike
Tanja Južnič Šetina, 2017, dictionary, encyclopaedia, lexicon, manual, atlas, map

Keywords: etiologija, komplikacije, recidiv, bolniki, psihološka pomoč
Published in DiRROS: 04.06.2020; Views: 1962; Downloads: 582
.pdf Full text (1,15 MB)

9.
10.
Search done in 0.33 sec.
Back to top